<DOC>
	<DOC>NCT00349518</DOC>
	<brief_summary>The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. The efficacy of the drug in this kind of patients will also further be documented.</brief_summary>
	<brief_title>Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Males and females, 18 or older CP or AD CML or Ph+ ALL Intolerant of resistant to imatinib ECOG PS 02 (CP CML) ECOG PS 03 (AD CML and Ph+ ALL) Adequate hepatic and renal function Pregnant or breastfeeding females History of significant cardiac disease History of significant bleeding disorder (not CML)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Chronic and Advanced Phase CML and</keyword>
	<keyword>Philadelphia Chromosome Positive ALL with imatinib intolerance or resistance</keyword>
</DOC>